Azilect and Zelapar will be two new alternatives for Parkinson's

July 2006

Azilect and Zelapar will be two new alternatives for Parkinson's.

Azilect (rasagiline) is an MAO-B inhibitor similar to selegiline. It works by blocking the breakdown of dopamine.

Azilect can be used as initial therapy...to improve symptoms in patients with early Parkinson's.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote